|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1995
|
|
gptkbp:atccode
|
J05 AF05
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioavailability
|
approximately 86%
|
|
gptkbp:brand
|
gptkb:3_TC
gptkb:Epivir
|
|
gptkbp:can_be_combined_with
|
gptkb:abacavir
gptkb:tenofovir
gptkb:emtricitabine
|
|
gptkbp:casnumber
|
134678-17-4
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C8 H11 N3 O3 S
|
|
gptkbp:clinical_trial
|
ongoing research for HIV treatment
studies for hepatitis B treatment
|
|
gptkbp:composed_by
|
chemical synthesis process
from 2',3'-dideoxy-5-fluorocytidine
from 2',3'-dideoxycytidine
|
|
gptkbp:contraindication
|
hypersensitivity to lamivudine
|
|
gptkbp:discovered_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:drug_interactions
|
gptkb:didanosine
gptkb:stavudine
gptkb:zidovudine
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral solution
combination tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lamivudine
|
|
gptkbp:invention
|
gptkb:2011
|
|
gptkbp:lifespan
|
5 to 7 hours
|
|
gptkbp:marketed_as
|
gptkb:Epivir
many countries worldwide
|
|
gptkbp:mechanism_of_action
|
reverse transcriptase inhibitor
|
|
gptkbp:name
|
essential medicines
|
|
gptkbp:pharmacokinetics
|
inhibits viral replication
rapid absorption
high plasma concentration
reduces viral load
|
|
gptkbp:price
|
low-cost generic available
|
|
gptkbp:provides_guidance_on
|
recommended for HIV therapy
recommended for hepatitis B therapy
|
|
gptkbp:research_focus
|
long-term effects
combination therapies
HIV resistance
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
lactic acidosis
neuropathy
pancreatitis
hepatomegaly
|
|
gptkbp:used_for
|
treatment of HIV
treatment of hepatitis B
|
|
gptkbp:bfsParent
|
gptkb:DNA-dependent_DNA_polymerase
|
|
gptkbp:bfsLayer
|
5
|